The International Pharmaceutical Aerosol Consortium (IPAC) is a group of companies that research and develop medicines, including metered dose inhalers (MDIs), to treat respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD). IPAC was formed in response to the international community’s mandate to phase out CFCs around the world. The unprecedented transition of life-saving medicines for environmental objectives presented numerous challenges, but also generated many opportunities to improve medical devices and enhance patient care. IPAC congratulates the Parties on three decades of dedication to healing the ozone layer, while recognizing technological, economic, and health realities. The Montreal Protocol Parties’ focus on pragmatic, sustainable solutions is an inspiring model for other international frameworks. IPAC commends the Technological and Economic Assessment Panel – and the Medical and Chemical Technical Options Committee – for their expertise, hard work, and patience in providing sound guidance and recommendations to the Parties over thirty years.